Coumadin

(Warfarin)

ApprovedSmall molecule

Warfarin is a blood thinner used to prevent blood clots that could cause strokes, heart attacks, or other serious conditions. It's commonly prescribed to patients with irregular heartbeat, those who have had blood clots, or people with certain heart valve replacements.[2] Coumadin is currently approved and in use across 48 indications[4].[1]

Coumadin is one of 795 small molecule programs targeting Pulmonary Embolism. It is currently in Approved.

Indications

315

Total Trials

Active Trials

794

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Pulmonary EmbolismTerminated

Coronary Artery BypassUnknown status

Overactive BladderApproved

Parkinson DiseaseApproved

EpilepsyCompleted

Heart Valve DiseaseApproved

Peripheral Vascular DiseaseApproved

Cardiovascular DiseaseApproved

Lymphoid NeoplasmApproved

Heart DiseaseApproved

Pulmonary EmbolismApproved

Terminated

Coronary Artery BypassApproved

Unknown status

Overactive BladderApproved

Approved

Parkinson DiseaseApproved

Approved

EpilepsyApproved

Completed

Heart Valve DiseaseApproved

Approved

Peripheral Vascular DiseaseApproved

Approved

Cardiovascular DiseaseApproved

Approved

Lymphoid NeoplasmApproved

Approved

Heart DiseaseApproved

Approved

Showing 10 of 46 indications

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Coumadin

AAbbott

Approved

1 2

Amidate

Pfizer

Preclinical

1 3

Adriamycin

Savaysa

Xifaxan

2 6

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 8

Potassium Iodide

MMeda Pharmaceuticals

Preclinical

1 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

Neo-Synephrine

EExela Pharma Sciences, LLC.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalActive, not recruiting

Atrial Fibrillation

NCT04045093

Q4 2027

N/ARecruiting

Prosthetic Valve Thrombosis

NCT02318342

Post-ApprovalRecruiting

Mitral Valve Repair

NCT06738992

Q3 2028

Post-ApprovalRecruiting

Acute Myocardial Infarction

NCT06515730

Q2 2030

N/AActive, not recruiting

Trial

NCT06449469

Clinical

Trials by Indication[1]

Atrial Fibrillation35 trials

"ORBIT" Versus "HAS-BLED" Scores in Predicting Major Bleeding in Patients With Atrial Fibrillation Receiving Oral Anticoagulants.

Unknown status·SSohag University··NCT05975320·100 enrolled

Short Term Warfarin Therapy for Radiofrequency Catheter Ablation of Atrial Fibrillation

Unknown status·KKorea University Anam Hospital·N/A·NCT01991951·520 enrolled

Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation

Completed·—·Phase 4·NCT02942407·154 enrolled

Show 32 more trials

A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation

Completed· Astellas logo

Astellas·Phase 2·NCT00938730·1,280 enrolled

ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)

Completed·UUniversity of Pavia·Phase 4·NCT02935855·300 enrolled

Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis

Completed·UUnity Health Toronto·Phase 2·NCT03987711·151 enrolled

Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation

Terminated·MMayo Clinic·Phase 3·NCT03839355·34 enrolled

Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

Completed·BBoston Scientific Corporation·Phase 3·NCT01182441·407 enrolled

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)

Completed· Bayer logo

Bayer··NCT04249401·134,897 enrolled

Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT03596502·402,764 enrolled

BAY59-7939 in Atrial Fibrillation Once Daily (OD)

Completed· Bayer logo

Bayer·Phase 2·NCT00973245·102 enrolled

Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis

Recruiting·SSung-Hwan Kim·Phase 2·NCT05540587·240 enrolled

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

Completed·IIntermountain Health Care, Inc.·Phase 4·NCT03061006·101 enrolled

Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation

Completed· Pfizer logo

Pfizer··NCT05321810·193,565 enrolled

EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation

Terminated·EElectrophysiology Research Foundation·Phase 4·NCT02561897·5 enrolled

Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

Completed·—·Phase 4·NCT03463317·912 enrolled

DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT00806624·234 enrolled

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT00781391·21,105 enrolled

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.

Terminated· Bayer logo

Bayer··NCT03715725·70,000 enrolled

A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation

Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University·N/A·NCT03792152·80 enrolled

Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

Completed· Pfizer logo

Pfizer··NCT05438888·77,814 enrolled

A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01136408·174 enrolled

Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively

Terminated·HHospital Ana Nery·Phase 2/3·NCT01868243·27 enrolled

A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin

Completed· Bayer logo

Bayer··NCT05022758·45,000 enrolled

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02769078·14,201 enrolled

Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Completed· Astellas logo

Astellas·Phase 2·NCT00448214·448 enrolled

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00580216·3,773 enrolled

Dabigatran for Mitral Stenosis Atrial Fibrillation

Active, not recruiting·TThe University of Hong Kong·Phase 4·NCT04045093·370 enrolled

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT02072434·2,199 enrolled

Hirudin Plus Aspirin in the Secondary Prevention of Cardioembolic Stroke Due to Nonvalvular Atrial Fibrillation

Completed·XXijing Hospital··NCT02181361·239 enrolled

Left Atrial Appendage (LAA) Occluders After Catheter Ablation of Atrial Fibrillation

Completed·MMeshalkin Research Institute of Pathology of Circulation·Phase 2·NCT01695824·96 enrolled

Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease

Completed·—·Phase 4·NCT02982850·120 enrolled

A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes

Completed· Bayer logo

Bayer··NCT04509193·116,049 enrolled

Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty

Unknown status·—··NCT04878497·1,000,000 enrolled

Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)

Completed·MMassachusetts General Hospital·Phase 3·NCT00000517

Interaction19 trials

Drug Interaction Study of Warfarin and MT-3995

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 1·NCT02531568·20 enrolled

A Drug Interaction Study of LY3871801 in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05602675·39 enrolled

A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05445232·32 enrolled

Show 16 more trials

Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT01657825·20 enrolled

Drug Interaction Study Between AZD3480 and Warfarin

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00689637·26 enrolled

Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02783040·13 enrolled

A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01388335·13 enrolled

A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01199341·28 enrolled

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Completed· Astellas logo

Astellas·Phase 1·NCT01911728·14 enrolled

A Drug Interaction Study of Danicopan

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04709094·52 enrolled

Drug Interaction Study of Rifampin and Warfarin in Healthy Volunteers.

Completed·UUniversity of California, San Francisco·N/A·NCT00777855·10 enrolled

Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

Completed·KKnopp Biosciences·Phase 1·NCT01597310·15 enrolled

A Drug-Drug Interaction Study of Warfarin and PA21

Completed·VVifor Pharma·Phase 1·NCT01477424·45 enrolled

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Completed·MMirati Therapeutics Inc.·Phase 1·NCT04887194·40 enrolled

Drug-drug Interaction Study(Lobeglitazone, Warfarin)

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 1·NCT02002611·24 enrolled

Pharmacokinetic Drug-Drug Interaction Study of Rucaparib

Completed·Ppharmaand GmbH·Phase 1·NCT02740712·17 enrolled

Interaction Between ABT-335, Rosuvastatin and Warfarin

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00487136·45 enrolled

Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Administration of K-877 on the Pharmacodynamics and the Pharmacokinetics of Multiple-Dose Administration of Warfarin in Healthy Adult Volunteers

Completed·KKowa Research Institute, Inc.·Phase 1·NCT02719431·20 enrolled

A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02540668·15 enrolled

Venous Thromboembolism9 trials

Direct Oral Anticoagulants and Venous Thromboembolism

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02833987·59,525 enrolled

D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism

Terminated·UUniversità degli Studi dell'Insubria·N/A·NCT00428441·73 enrolled

Prevention of Recurrent Venous Thromboembolism (PREVENT)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000614

Show 6 more trials

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Completed· Bayer logo

Bayer·Phase 3·NCT01516840·60 enrolled

Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

Completed· Bayer logo

Bayer·Phase 3·NCT01516814·40 enrolled

Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00291330·2,564 enrolled

Treatment Patterns Among Patients With Venous Thromboembolism in the United States

Completed· Pfizer logo

Pfizer··NCT05795062·13,945 enrolled

Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

Completed· LEO Pharma logo

LEO Pharma·Phase 3·NCT01130025·900 enrolled

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00680186·2,589 enrolled

Anticoagulant8 trials

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01431690·52 enrolled

Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04879407·98,947 enrolled

Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants

Completed·AAzienda Ospedaliera Universitaria Policlinico·Phase 4·NCT00438230·250 enrolled

Show 5 more trials

Start or STop Anticoagulants Randomised Trial (SoSTART)

Completed·UUniversity of Edinburgh·Phase 3·NCT03153150·203 enrolled

Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04593056·102,636 enrolled

Replication of the RELY Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04593043·78,140 enrolled

Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04593030·220,518 enrolled

Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04736719·19,002 enrolled

Anticoagulation7 trials

Anticoagulation for Aortic Bioprosthesis (ANTIPRO)

Completed·IInstituto Nacional de Cirugia Cardiaca, Uruguay·Phase 4·NCT03807921·140 enrolled

Genetic Determinants of Warfarin Anticoagulation Effect

Unknown status·HHadassah Medical Organization·N/A·NCT00162435·500 enrolled

The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The "INRange" RCT

Completed·UUniversity of Alberta·Phase 4·NCT02376803·217 enrolled

Show 4 more trials

Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT04066764·200 enrolled

Anticoagulation Regiments in Patients With Prosthetic Heart Valve Thrombosis

Unknown status·KKartal Kosuyolu Yuksek Ihtisas Education and Research Hospital·N/A·NCT02240953·180 enrolled

Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service

Completed·—·N/A·NCT02392104·51 enrolled

Anticoagulation Regimens in Pregnant Patients With Prosthetic Heart Valves

Unknown status·KKartal Kosuyolu Yuksek Ihtisas Education and Research Hospital·N/A·NCT02240927·40 enrolled

75 more indications

Tics6 trials

Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Completed·BBial - Portela C S.A.·Phase 1·NCT02779348·16 enrolled

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Completed·BBial - Portela C S.A.·Phase 1·NCT02169440·20 enrolled

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00914667·14 enrolled

Show 3 more trials

A Pharmacokinetics, Pharmacodynamics and Safety Study of Warfarin in Combination With Tamiflu (Oseltamivir)

Completed· Roche logo

Roche·Phase 4·NCT02780622·20 enrolled

Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics

Completed·BBial - Portela C S.A.·Phase 1·NCT04994119·26 enrolled

Effect of Opicapone at Steady State on Warfarin Pharmacokinetics

Completed·BBial - Portela C S.A.·Phase 1·NCT02305030·20 enrolled

Rivaroxaban6 trials

A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01400646·46 enrolled

Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis

Terminated·HHospital Geral Roberto Santos·Phase 2/3·NCT03566303·50 enrolled

Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium

Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 4·NCT02376010·110 enrolled

Show 3 more trials

Switching Study From Warfarin to Rivaroxaban

Completed· Bayer logo

Bayer·Phase 1·NCT01507051·96 enrolled

Efficacy Comparison of Warfarin Versus Rivaroxaban CVT

Unknown status·IIsfahan University of Medical Sciences·Phase 1/2·NCT03747081·50 enrolled

Rivaroxaban vs. Warfarin in CVT Treatment

Completed·—·Phase 3·NCT04569279·71 enrolled

Midazolam4 trials

Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02345304

A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Midazolam and Warfarin in Healthy Male Subjects

Completed· Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.·Phase 1·NCT05480488·18 enrolled

The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02254148·24 enrolled

Show 1 more trial

A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02617810·18 enrolled

Pulmonary Embolism4 trials

STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism

Unknown status·UUniversity of Birmingham·Phase 3·NCT04727437·1,466 enrolled

Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement

Completed·—·Phase 4·NCT02810704·18,883 enrolled

Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy

Unknown status·MMeshalkin Research Institute of Pathology of Circulation·Phase 4·NCT02979561·200 enrolled

Show 1 more trial

XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis

Terminated·SSusan Smyth·Phase 4·NCT02506985·10 enrolled

Oral3 trials

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06215430·16 enrolled

A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT03058419·16 enrolled

Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices

Completed·PPalak Shah·Phase 2·NCT04865978·30 enrolled

Portal vein thrombosis3 trials

TIPS for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis and CTPV

Unknown status·ZZaibo Jiang·Phase 3·NCT02853526·100 enrolled

Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）

Completed·NNorthern Jiangsu People's Hospital·Phase 4·NCT04645550·120 enrolled

Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy

Unknown status·YYangzhou University·Phase 4·NCT02238444·60 enrolled

Venous thrombosis3 trials

Acute Mesenteric Venous Thrombosis.. in Assiut University Hospital Management Controversies

Unknown status·—·N/A·NCT03483207·30 enrolled

Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs.

Unknown status·—·N/A·NCT02704598·84 enrolled

The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis

Unknown status·—·Phase 3·NCT03217448·80 enrolled

Trial3 trials

Arterial Disease Multifactorial Intervention Trial (ADMIT)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000539

The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)

Active, not recruiting·RRigshospitalet, Denmark·N/A·NCT06449469·352 enrolled

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Terminated·AArtivion Inc.·Phase 3·NCT04142658·863 enrolled

Deep Vein Thrombosis3 trials

The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis

Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT00216866·70 enrolled

Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT04067505·224 enrolled

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00643201·5,614 enrolled

Treatment3 trials

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01561937·127 enrolled

Treatment for Blood Clots in the Veins of the Legs

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00001713·20 enrolled

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT00986154·8,292 enrolled

Efficacy and Safety3 trials

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT01662908·85 enrolled

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02913326·120 enrolled

Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)

Completed·YYonsei University·Phase 3·NCT03244319·220 enrolled

Adult Subject2 trials

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03363815·56 enrolled

Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects

Completed· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT02461914·16 enrolled

Gastric Emptying2 trials

Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects

Completed·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 1·NCT06723691·57 enrolled

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

Completed·IIntarcia Therapeutics·Phase 1·NCT02641899·33 enrolled

Pilot Study2 trials

Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection

Withdrawn·UUniversity of California, San Diego·Phase 1·NCT00265408

Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study

Withdrawn·MMayo Clinic·Phase 2·NCT02450682

Antiphospholipid Syndrome2 trials

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome

Completed·—·Phase 4·NCT02295475·48 enrolled

RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome

Unknown status·UUniversity College, London·Phase 2·NCT03684564·43 enrolled

Prospective2 trials

MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)

Unknown status·IInstitute for Clinical and Experimental Medicine·N/A·NCT03078374·15 enrolled

Evaluation of Maintenance Dosing vs Loading Dosing Upon Restarting Warfarin Therapy: A Prospective Randomized Trial

Completed·UUniversity of Alberta·Phase 1·NCT01124058·39 enrolled

Stroke2 trials

PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01227629·502 enrolled

Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

Completed·UUniversity of South Florida·Phase 3·NCT02283294·91 enrolled

Semaglutide2 trials

Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02022254·24 enrolled

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02070510·52 enrolled

Hip Arthroplasty1 trial

Evaluation of Wound Drainage After Knee or Hip Arthroplasty

Withdrawn·UUniversity of Michigan·Phase 4·NCT02054936

ART1 trial

A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01825876·17 enrolled

Alveolar Soft Part Sarcoma1 trial

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01391962·34 enrolled

Atopic Dermatitis1 trial

Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

Completed· Regeneron logo

Regeneron·Phase 1·NCT02647086·14 enrolled

Drug1 trial

A Drug Drug Interaciton Study of Imrecoxib and Warfarin in Healthy Volunteers

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02426060·12 enrolled

Patients With Advanced Solid Tumors1 trial

Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT00091299·24 enrolled

Solid Tumors1 trial

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT01340846·48 enrolled

Rheumatoid Arthritis1 trial

A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01636557·12 enrolled

Overweight1 trial

A Study of BGM0504 in Overweight or Obese Participants

Completed·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 1·NCT06920056·28 enrolled

Antiplatelet Therapy1 trial

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

Completed·AAbbott Medical Devices·Phase 4·NCT02836652·72 enrolled

Ulcerative Colitis1 trial

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT03358706·28 enrolled

Psoriatic Arthritis1 trial

This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis

Completed· AbbVie logo

AbbVie·Phase 1·NCT02772601·21 enrolled

Pancreatic Cancer1 trial

Biological Effect of Warfarin on Pancreatic Cancer

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT03536208

MPA1 trial

Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02183389·18 enrolled

Drug Interactions1 trial

Human Cytochrome P450 4F Enzymes and Drug Interactions

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT01250535·19 enrolled

Age1 trial

Clinical and Economic Implications of Genetic Testing for Warfarin Management

Completed·UUniversity of Chicago·Phase 4·NCT00964353·359 enrolled

Thrombocytopenia1 trial

Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

Terminated·UUniversity of Louisville·Phase 2·NCT00673439·3 enrolled

Prosthetic Valve Thrombosis1 trial

Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation

Recruiting·—·N/A·NCT02318342·3,000 enrolled

Antiplatelet1 trial

Warfarin and Antiplatelet Vascular Evaluation

Unknown status·—·Phase 3·NCT00125671·2,400 enrolled

Catheter1 trial

Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters

Completed·CCancer Research Campaign Clinical Trials Centre·N/A·NCT00024297

Patent foramen ovale1 trial

Patent Foramen Ovale in Cryptogenic Stroke Study

Completed·—·Phase 4·NCT00697151·630 enrolled

Left Ventricular Thrombus1 trial

Apixaban in Patients With Left Ventricular Thrombus

Completed·SSaud Al Babtain Cardiac Center·Phase 3·NCT05208398·50 enrolled

Coronary Artery Bypass1 trial

Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery

Unknown status·UUniversity of Sao Paulo General Hospital·Phase 4·NCT05300555·50 enrolled

Monotherapy1 trial

Anti-thrombotic Monotherapy in HeartMate 3 Left Ventricular Assist System (LVAS)

Unknown status·IInstitute for Clinical and Experimental Medicine·N/A·NCT03781258·20 enrolled

Knee Replacement Surgery1 trial

Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery

Unknown status·TThe New England Baptist Hospital·N/A·NCT00767559·330 enrolled

Complication1 trial

NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications

Completed·MMalmö University··NCT04662515·216 enrolled

AML1 trial

An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

Active, not recruiting· Sanofi logo

Sanofi·Phase 1·NCT06686628·23 enrolled

Pregnant Women1 trial

Use of Warfarin After the First Trimester in Pregnant Women With APS

Unknown status·MMohamed Sayed Abdelhafez·Phase 4·NCT02303171·100 enrolled

Cognitive impairment1 trial

Cognitive Impairment Related to Atrial Fibrillation Prevention Trial

Completed·UUniversity of Sao Paulo·Phase 4·NCT01994265·200 enrolled

Atorvastatin1 trial

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06289504·34 enrolled

Uterine Bleeding1 trial

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT04394234·961,985 enrolled

Length of Stay1 trial

Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02631057·4,313 enrolled

Cognition1 trial

AntiCoagulants and COGnition

Unknown status·UUniversity Hospital, Angers·Phase 4·NCT04073316·48 enrolled

Metabolism1 trial

Determinants of Warfarin Metabolism

Unknown status·HHadassah Medical Organization·N/A·NCT00162474·600 enrolled

Thrombosis1 trial

Treatment of Upper Extremity Deep-Vein Thrombosis

Completed·UUniversity of Oklahoma·Phase 4·NCT00245856·67 enrolled

Acute Myocardial Infarction1 trial

Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction

Recruiting·KKarolinska Institutet·Phase 4·NCT06515730·212 enrolled

Direct Oral Anticoagulants (DOACs)1 trial

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

Completed·AAlliance Foundation Trials, LLC.·N/A·NCT02744092·811 enrolled

AIN1 trial

The Study of Warfarin Maintenance Dose in Chinese Patients

Unknown status·—··NCT01855737·1,000 enrolled

Pulmonary Hypertension1 trial

Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT01036802·3 enrolled

Factor Xa Inhibitor1 trial

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

Completed·PPortola Pharmaceuticals·Phase 2·NCT00742859·508 enrolled

Heart1 trial

Dabigatran Etexilate in Patients With Mechanical Heart Valves

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01452347·328 enrolled

Overweight or Obese1 trial

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05815680·48 enrolled

Mitral Valve Repair1 trial

Safety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair

Recruiting·GGuangdong Provincial People's Hospital·Phase 4·NCT06738992·384 enrolled

Empagliflozin1 trial

Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01111331·18 enrolled

Telitacicept1 trial

Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE

Unknown status·QQilu Hospital of Shandong University··NCT05644210·80 enrolled

Oligohydramnios1 trial

Warfarine in Unexplained Oligohydramnios

Terminated·WWoman's Health University Hospital, Egypt·Phase 4·NCT01569035·200 enrolled

ARDS1 trial

Assessment of 2012 Bioequivalence Standards for Warfarin

Completed·UUniversity of California, San Francisco·Phase 1·NCT02574754·10 enrolled

Prostate Cancer1 trial

Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00014352

Idiopathic Pulmonary Fibrosis1 trial

AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Terminated·—·Phase 3·NCT00957242·145 enrolled

TIA1 trial

Validation of Predictors of OAC Initiation Using EMR Data

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03006341·140,187 enrolled

Post-Operative Atrial Fibrillation1 trial

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

Completed·SSanford Health·Phase 2/3·NCT02889562·56 enrolled

Hemorrhage1 trial

Hemorrhage Following Small Polyp Resection in the Colon in Anticoagulated Patients

Unknown status·HHadassah Medical Organization·N/A·NCT02375646·286 enrolled

Effectiveness1 trial

Comparative Effectiveness and Safety Between Warfarin and Dabigatran

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03254134·22,490 enrolled

Hepatitis C Virus Infection1 trial

Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection

Completed·IImperial College London·Phase 2·NCT00180674·14 enrolled

Elderly Patients1 trial

Validation of International Warfarin Pharmacogenetics Consortium (IWPC) Algorithm in Elderly Patients With Comorbidity

Unknown status·UUniversity of Campania Luigi Vanvitelli··NCT02069132·376 enrolled

After Cardiac Surgery1 trial

DOAC Versus VKA After Cardiac Surgery

Withdrawn·LLaval University·Phase 2·NCT04002011

Unspecified11 trials

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

Completed·BBial - Portela C S.A.·Phase 1·NCT02287415·13 enrolled

Warfarin Patient Self-Monitoring

Completed·UUniversity of British Columbia·N/A·NCT00925028·25 enrolled

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02164864·2,725 enrolled

Show 8 more trials

A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT02252731·22 enrolled

Duloxetine - Warfarin Pharmacodynamic Study

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT00533026·60 enrolled

Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information

Completed·—·N/A·NCT00401414·344 enrolled

Follow on Study From RE-ALIGN

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01505881·158 enrolled

A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers

Completed· GSK logo

GSK·Phase 1·NCT00404274·97 enrolled

Medical Need of OAC Reversal

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03254147·53,969 enrolled

Dabigatran Versus Warfarin With NVAF Who Undergo PCI

Unknown status·SShenyang Northern Hospital·Phase 4·NCT03536611·1,120 enrolled

RIvoraxaban in Mitral Stenosis

Terminated·RRajaie Cardiovascular Medical and Research Center·Phase 3·NCT03926156·40 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

ATHROMBIN

NDA NDA011771

Jan 1, 1982

PANWARFIN

NDA NDA017020

Feb 7, 1995

COUMADIN

NDA NDA009218

Sources

References

[1]
ClinicalTrials.gov — 315 trial records for Warfarin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Coumadin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Warfarin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Warfarin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA009218). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Abbott company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Vitamin K Epoxide Reductase Complex Subunit 1 Isoform 1 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AAbbott